Author:
Buyse Marc,Sargent Daniel J.,Grothey Axel,Matheson Alastair,de Gramont Aimery
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971–983 (2006).
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
3. Temple, R. J. A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation (Eds Nimmo, W. S. & Tucker, G. T.) 17 (Wiley, New York, 1995).
4. Ransohoff, D. F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4, 309–314 (2004).
5. Goodsaid, F. M., Frueh, F. W. & Mattes, W. Strategic paths for biomarker qualification. Toxicology 245, 219–223 (2008).
Cited by
268 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献